About: Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
Creator	Al-Kali, A Bewersdorf, J Bewersdorf, R Boddu, J Boddu, P Comprehensive, Yale Deangelo, D Goldberg, A Mbbs, Patnaik Mbbs, Zeidan Rampal, R Shallis, Yale Stahl, M Stein, E Zeidan, P
Source	Elsevier; Medline; PMC
abstract	The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1016/s2352-3026(20)30205-2
bibo:pmid	32563283
has license	no-cc
sha1sum (hex)	fcd9479e8b0570ba8db098e04521d54d793a7eac
schema:url	https://doi.org/10.1016/s2352-3026%2820%2930205-2
resource representing a document's title	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
has PubMed Central identifier	PMC7302757
has PubMed identifier	32563283
schema:publication	Lancet Haematol
resource representing a document's body	covid:fcd9479e8b0570ba8db098e04521d54d793a7eac#body_text
is schema:about of	named entity 'environment' named entity 'caused' named entity 'ethical' named entity 'service' named entity 'MEASURES' named entity 'TO PROVIDE' named entity 'HIGH' named entity 'COUNTRIES' named entity 'COMPLEX' named entity 'ONGOING' named entity 'RECOMMENDATIONS' named entity 'patients' named entity 'basis' named entity 'COVID-19' named entity 'supportive care' named entity 'Multiple' named entity 'high-income countries' named entity 'neoplasms' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'leukaemias' named entity 'supportive care' named entity 'clinical trial' named entity 'general population' named entity 'ongoing COVID-19 pandemic' named entity 'prophylactic' named entity 'cross-matching' named entity 'remdesivir' named entity 'haematological malignancies' named entity 'Clinical trials' named entity 'resource allocation' named entity 'case fatality rate' named entity 'patient care' named entity 'azacitidine' named entity 'pharmacodynamic' named entity 'supportive care' named entity 'immunosuppression' named entity 'physical distancing' named entity 'drug-drug interactions' named entity 'anticoagulation' named entity 'haemoglobin' named entity 'higher risk' named entity 'platelet' named entity 'antibacterial' named entity 'physical distancing' named entity 'myeloproliferative neoplasms' named entity 'haematological malignancies' named entity 'stem-cell' named entity 'broadspectrum' named entity 'COVID-19' named entity 'blood products' named entity 'haematological malignancies' named entity 'erythropoiesis-stimulating agents' named entity 'antifungal' named entity 'haematological malignancies' named entity 'relapse' named entity 'blood products' named entity 'oncologists' named entity 'anaemia' named entity 'antiviral therapies' named entity 'oncology' named entity 'inflammatory responses' named entity 'COVID' named entity 'outpatient' named entity 'infection' named entity 'clinical trials' named entity 'North America' named entity 'haematopoietic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software